New Hampshire 2026 Regular Session

New Hampshire Senate Bill SB256

Introduced
1/23/25  
Refer
1/23/25  
Refer
2/21/25  
Refer
3/6/25  
Report Pass
10/22/25  
Engrossed
2/26/26  
Refer
2/26/26  

Caption

Establishing safety and care requirements for clinician-administered drugs.

Impact

The legislation seeks to replace existing practices deemed risky, such as 'brown bagging', where patients transport their medication to healthcare providers. By enforcing stricter controls on how these drugs are handled, SB256 aims to safeguard the quality of care administered to patients and potentially reduce the risks associated with self-administration of drugs that should be given by professionals. It is anticipated this will also influence the insurance framework, as prohibiting certain practices could lead to changes in coverage policies and claims handling.

Summary

SB256 establishes new safety and care requirements for clinician-administered drugs in the state. The bill outlines that certain outpatient prescription drugs, which are not self-administered, must be administered by a healthcare professional. It introduces new regulations concerning the dispensation of these drugs, aiming to enhance patient safety and ensure that healthcare providers maintain full control over medication administration. Specifically, it prohibits health insurers and pharmacy benefit managers from mandating how these drugs are dispensed, thereby allowing more autonomy for patients and providers alike.

Sentiment

Overall sentiment around the bill appears to be positive among healthcare providers who support increased safety measures. Advocates believe that establishing formal requirements ensures better compliance with care standards and potentially mitigates risks for patients receiving clinician-administered drugs. However, there is concern among insurers about the potential financial implications, such as rising costs associated with coverage, which could affect insurance premiums for consumers.

Contention

Key points of contention revolve around the balance between ensuring patient safety and managing healthcare costs. Insurers have expressed worries over how the prohibition of 'brown bagging' may lead to increased costs, which could ultimately be passed onto consumers through higher premiums. Nonetheless, proponents argue that the safety of patients should take precedence over cost considerations. The ongoing debate highlights the complexities of healthcare policy, particularly the interplay between patient safety, regulatory controls, and healthcare economics.

Companion Bills

NH SB256

Carry Over Relative to the affordability and safety of clinician administered drugs.

Previously Filed As

NH SB256

Relative to the affordability and safety of clinician administered drugs.

NH SB130

Establishing a commission to study delivery models for emergency medical services in the state of New Hampshire.

NH HB377

Relative to health care professionals administering hormone treatments and puberty blockers and relative to recognizing the second Thursday in October as children's environmental health day.

NH SB129

Relative to establishing an uncompensated health care fund to be administered by the department of insurance and assessed by a surcharge on commercial insurers, reinsurers, and trusts overseeing self-insured plans.

NH SB15

Relative to establishing a mandatory minimum sentence for the crime of distribution of a controlled drug with death resulting.

NH HB648

Relative to insurance coverage for glucose monitoring.

NH HB645

Relative to data collection and reporting requirements of the prescription drug affordability board.

NH SB244

Relative to expanding access to primary health care services, increasing the size of the health care workforce, and making appropriations therefor.

NH HB756

Relative to establishing a blood lead level testing requirement for children entering daycare and public schools.

NH SB125

Relative to clinical eligibility criteria for nursing facility and home and community based care.

Similar Bills

MA H4956

Relating to patient choice in dispensing of clinician-administered drugs

MA H1313

Relating to patient choice in dispensing of clinician-administered drugs

MO SB13

Enacts provisions relating to insurance coverage of pharmacy services

NH SB256

Relative to the affordability and safety of clinician administered drugs.

NE LB109

Prohibit certain provisions in insurance policies and health plans relating to clinician-administered drugs and change provisions relating to pharmacy benefit managers

MO SB846

Enacts provisions relating to insurance coverage of health care services

AZ SB1710

Pharmacy benefits; patient steering; prohibition

NE LB533

Provide requirements relating to clinician-administered drugs under the Pharmacy Benefit Manager Licensure and Regulation Act